Photodiagnosis and photodynamic therapy · 2025
Deep-targeted photodynamic therapy: A patented drug delivery system for total urethral condylomata acuminata.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Junpeng, Shen Jing, Liu Hui, Li Shujiao, Peng Xiaoming, Yang Yang, Xu Meinian, Zeng Kang
Аннотация
BACKGROUND: Treating total urethral condyloma acuminata (CA) remains challenging. Although 5-aminolevulinic acid photodynamic therapy (5-ALA-PDT) is a recommended first-line treatment for mucosal CA, conventional drug delivery fails to cover deep urethral lesions, often leading to recurrence.
OBJECTIVE: To evaluate a novel self-developed drug delivery system designed to improve deep drug administration for 5-ALA-PDT in total urethral CA, aiming to enhance efficacy and reduce recurrence.
METHODS: The system utilizes a specialized design to deliver 5-ALA to deep urethral areas. A representative case involved a patient with recurrent urethral CA (12 cm from meatus) after multiple laser and traditional PDT treatments. He received eight 5-ALA-PDT sessions with the new system.
RESULTS: The system effectively delivered 5-ALA to deep lesions. The patient achieved virological clearance (undetectable HPV DNA) at 6 months, sustained through 8-month follow-up, with significant symptom improvement.
CONCLUSION: This novel delivery system enables precise 5-ALA administration to deep urethral lesions and latent HPV zones, improving treatment completeness and clinical outcomes for total urethral CA.
OBJECTIVE: To evaluate a novel self-developed drug delivery system designed to improve deep drug administration for 5-ALA-PDT in total urethral CA, aiming to enhance efficacy and reduce recurrence.
METHODS: The system utilizes a specialized design to deliver 5-ALA to deep urethral areas. A representative case involved a patient with recurrent urethral CA (12 cm from meatus) after multiple laser and traditional PDT treatments. He received eight 5-ALA-PDT sessions with the new system.
RESULTS: The system effectively delivered 5-ALA to deep lesions. The patient achieved virological clearance (undetectable HPV DNA) at 6 months, sustained through 8-month follow-up, with significant symptom improvement.
CONCLUSION: This novel delivery system enables precise 5-ALA administration to deep urethral lesions and latent HPV zones, improving treatment completeness and clinical outcomes for total urethral CA.